MOUSE RECOMBINANT CB2 RECEPTOR
MULTISCREENTM Β-ARRESTIN2 STABLE CELL LINE
1 vial (2 x 106) frozen cells
Expression vector containing full-length mouse CNR2 cDNA (GenBank Accession Number NM_009924.4) with FLAG tag sequence at N-terminus and ARRB2 cDNA (GenBank Accession Number NM_004313.3)
Liquid nitrogen upon receiving
Propagation Medium: DMEM/F12, 10% FBS, 10 ug/ml puromycin, 800 ug/ml G418
Stability: Stable for a minimum of 2 months in continuous culture
Background: Cannabinoid receptor 2 (CB2) is expressed in peripheral and immune tissues. CB2 in rodents is involved not only in processes of regulation of bone homeostasis but also in cannabinoid-induced central nerve system effects. This receptor can serve as potential therapeutic target in the treatment of various disorders affecting central nerve system or skeletal homeostasis. It was also demonstrated that CB2 receptor is involved in the reduction of chemotherapy-induced allodynia.
Application: Functional assays
Figure 1. Dose-dependent stimulation from arrestin recruitment upon treatment with ligand, measured with MULTISCREEN™ β-Arrestin Assay Kit (Multispan MSBA01) Figure 2. Dose-dependent inhibition of forskolin-stimulated intracellular cAMP level upon treatment with ligand, measured with MULTISCREEN™ TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01). Figure 3. Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Gong et al. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in the rat brain. Brain research, 1071(1), 10-23.
Raphael-Mizrahi and Gabet (2020). The cannabinoids effect on bone formation and bone healing. Curr. Osteoporos, 18(5), 433-438.
O’Hearn et al. (2017). Modulating the endocannabinoid pathway as treatment for peripherial neuropathic pain: a selected review of preclinical studies. Annals of palliative medicine, 6(Suppl 2), S209-S214.